BEND, Ore., June 27, 2011 /PRNewswire-USNewswire/ -- Bend Research Inc. (www.bendresearch.com), a leading independent drug-formulation development and manufacturing company, has named a new president.
Jim Nightingale, who has worked at the company since 1993, will be the fourth president in the firm's 36-year history.
Nightingale will succeed Rod Ray, who will continue in his capacity as Bend Research Chief Executive Officer (CEO) and chairman of the board of directors.
Ray announced Nightingale's promotion from Senior Vice President for Business Development and Strategic Alliances, calling the new president "a dogged pursuer of quality and timeliness for our customers."
"Jim cares deeply about the company and our mission of advancing our clients' best new medicines," Ray said.
He credited Nightingale with being instrumental in developing and implementing the business development strategy that transformed the company from an exclusive relationship with Pfizer to the multiclient success it now enjoys. In the two years since Bend Research and Pfizer ended the exclusive contract, the company has built a base of more than 70 clients, including most of the largest pharmaceutical companies in the world.
Nightingale will be responsible for nearly all operational aspects of the company, working with Ray and Lisa Graham, the company's Chief Operating Officer (COO). His business development duties will be assumed by David Lyon, Vice President—Research.
The changes free Ray to focus more on strategic planning and future opportunities for the company. Ray served as president of the privately held company since 2002. Previous presidents were Chris Babcock (1987-2002) and Harry Lonsdale (1975-1987).
Nightingale holds a master's degree and doctorate in bioengineering from the University of Washington, where he also received a bachelor's degree in chemical engineering